Jefferies cuts target to USD 34 for Solventum stock

Published on 10/15/2026 at 12:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Solventum stock costs EUR 77.40 on October 15, 2026 at Lang & Schwarz. Second-quarter sales rose 2.2 percent to USD 2.21 billion.

Investor dates and valuation

Jefferies cut its Solventum target from USD 43.00 to USD 34.00 on October 8, 2026.
Second-quarter 2026 sales rose 2.2 percent to USD 2.21 billion.
Solventum stock traded at EUR 77.40 at 12:39 p.m. CEST on October 15, 2026, at Lang & Schwarz.

Solventum, US83444M1018, Illustration mit AI erstellt.

Solventum (ISIN US83444M1018) was trading at EUR 77.40 at Lang & Schwarz on October 15, 2026, at 12:39 p.m. CEST. Jefferies cut its price target for the healthcare company from USD 43.00 to USD 34.00 on October 8, 2026, while keeping a Buy rating, according to Investing.com.

What does the target cut change?

The revised USD 34.00 target is materially below Jefferies' previous USD 43.00 level. The report kept its Buy view but cited Solventum's USD 8.9 billion backlog and projected adjusted third-quarter 2026 EBITDA of USD 152 million, according to Investing.com.

Second-quarter sales set the base

Solventum reported USD 2.21 billion in revenue for the second quarter of 2026, up 2.2 percent from the same quarter a year earlier. Adjusted diluted earnings per share reached USD 2.55, compared with USD 1.69 in the prior-year quarter, while organic sales increased 9.5 percent. The company also raised its full-year 2026 adjusted earnings-per-share guidance to USD 7.10-7.20 and projected free cash flow of USD 200-300 million, according to Solventum.

When is the next reporting date?

The next quarterly results are scheduled for November 5, 2026, according to ToAlpha. That date will give investors a new test of the raised 2026 outlook and the execution behind the planned Health Information Systems separation.

Stock valuation remains the market link

Solventum's market capitalization was USD 14.9 billion as of October 14, 2026. The primary-market 52-week range was USD 62.38 to USD 94.16, placing the latest US quote inside that band and keeping the analyst target debate central to the valuation discussion.